Morphine PCA vs Morphine and Lidocaine PCA for the treatment of vaso-occlusive crisis-related pain in sickle-cell anaemia patients: a prospective, randomized, double blind monocentric trial.

Status

Not yet recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-523777-41-01

Enrollment

Registered

2026-01-26

Start date

Unknown

Completion date

Unknown

Last updated

2026-01-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sickle cell anaemia

Brief summary

Reduction in morphine consumption

Detailed description

Evolution of biomarkers, Evolution of pain scores using the VAS score, Occurence of morphine-related adverse effects

Interventions

DRUGLIDOCAINE HYDROCHLORIDE

DRUGMORPHINE HYDROCHLORIDE

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Reduction in morphine consumption	—

Secondary

Measure	Time frame
Evolution of biomarkers, Evolution of pain scores using the VAS score, Occurence of morphine-related adverse effects	—

Countries

Belgium

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026